Robert Buckley, MD
Family Medicine · Columbus, MSNPI 1356314702
Payments from drug & device makers
Across 53 payments — averaging $24.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$264
- AbbVie$145
- Novo Nordisk$140
- Boston Scientific$120
- Pfizer$97
- Boehringer Ingelheim$78
- plus $466 from 15 others
What the payments were for
- Food & beverage$1,29999%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 5 | $264 |
| AbbVie | 7 | $145 |
| Novo Nordisk | 2 | $140 |
| Boston Scientific | 2 | $120 |
| Pfizer | 6 | $97 |
| Boehringer Ingelheim | 4 | $78 |
| Supernus Pharmaceuticals, Inc. | 4 | $72 |
| Ironshore Pharmaceuticals Inc. | 2 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $50 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $42 |
| GSK | 3 | $38 |
| Exact Sciences | 2 | $34 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Lilly USA, LLC | 1 | $26 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Harmony Biosciences LLC | 1 | $17 |
| Shield Therapeutics Inc | 1 | $15 |
| Amgen | 1 | $15 |
| Merck | 1 | $15 |
| Linus Health, Inc. | 1 | $14 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$125
- AIRSUPRA$125
- FARXIGA$103
- GENERAL - THERAPIES$101
How this compares
$1,311 in reported general payments places this provider in the 60th percentile of 971 family medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 56 | $53,894 |
| MounjaroTirzepatide | 33 | $39,263 |
| JardianceEmpagliflozin | 42 | $26,572 |
| JanuviaSitagliptin Phosphate | 20 | $21,616 |
| TradjentaLinagliptin | 31 | $18,813 |
| EliquisApixaban | 31 | $18,066 |
| LinzessLinaclotide | 22 | $16,877 |
| FarxigaDapagliflozin Propanediol | 16 | $14,646 |
| GlyxambiEmpagliflozin/Linagliptin | 12 | $7,359 |
| SynjardyEmpagliflozin/Metformin Hcl | 11 | $6,292 |
| Dexlansoprazole DrDexlansoprazole | 24 | $4,742 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $4,150 |
| Gabapentin | 202 | $3,107 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 13 | $2,789 |
| Potassium Chloride | 122 | $2,039 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Synjardy | $78 | $59,03696 claims |
| Novo NordiskOzempic | $140 | $53,89456 claims |
| Lilly USA, LLCMounjaro | $26 | $39,26333 claims |
| MerckJanuvia | $15 | $21,61620 claims |
| PfizerEliquis | $97 | $18,06631 claims |
| AbbVieLinzess | $145 | $16,87722 claims |
| AstraZenecaFarxiga | $264 | $14,64616 claims |
| GSKShingrix | $38 | $2,78913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 971 family medicine providers in Mississippi.
Other family medicine in Columbus
- Paul MatherneGulfport$14.4M
- Timothy QuinnRidgeland$8M
- Sean KerbyGulfport$6.6M
- Rambod RouhbakhshHattiesburg$6M
- Randall HulingOlive Branch$4.6M
- Demetri MarshallPort Gibson$3M
- Alexander OsowaJackson$2.2M
- Russell CarlisleWesson$1.6M
- Kristi TrimmRidgeland$1.2M
- Keith StokesLexington$660K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.